MNKD : Analysis & Opinions

  1. Is This Why MannKind Investors Are Bullish?

    March 18, 2015
    Although MannKind (NASDAQ: MNKD) stumbled along the way toward the launch of its inhaled-insulin drug, Afrezza, many believe ...
  2. Why Does Wall Street Hate MannKind?

    March 9, 2015
    Since peaking, MannKind's shares have tumbled 25% due in large part to Wall Street's bearish outlook. Are Wall Street analysts ...
  3. Will MannKind Finally Reach A Solid Ground?

    March 2, 2015
    MannKind Corporation has been plagued by setbacks, but this year has turned into a pivotal one thanks to the launch of its ...
  4. Capitalize On This Small Stock's Insider Moves For 40% Upside

    October 25, 2013
    I couldn't believe my good fortune. It was my first day investing with real money at a proprietary trading firm. I had just ...
  5. Market Wrap for Wednesday, August 14: U.S. Stocks Fall Mid-Week; ...

    August 14, 2013
    The U.S. stock market fell for most of Wednesday's trading session, finishing near its worst levels of the day. The ...
  6. Investing For The Global Diabetes Epidemic

    May 31, 2013
    Sadly, diabetes is quickly becoming a global epidemic. Within these grim statistics, investors can find opportunities with ...
  7. 3 Stocks Ripe for Upside Reversals

    July 23, 2011
    Sentiment seems to be turning more favorable toward these three stocks, and given new insider buying, shares may be ready ...
  8. Should Biotech Investors Go Where Institutions Won't?

    July 7, 2011
    A lack of institutional ownership should be a warning sign for biotech investors.
  9. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  10. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  11. The Curious And Complicated Case Of MannKind

    December 15, 2010
    MannKind is a classic high-risk high-reward biotech story.
  12. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
Trading Center